Delivery of CXCL14 and E6/E7 epitopes un- der the control of a synthetic tumor-specific promoter is a promising strategy for novel adenoviral transgene immunotherapy to treat HPV+ HNSCC. This evidence concerns the gene CXCL14 and neoplasm.